Impact of surgical and medical castration on serum testosterone level in prostate cancer patients

Urologia Internationalis

Volumn 82, Issue 3, 2009, Pages 249-255

  Novara, Giacomo ^a   Galfano, Antonio ^a   Secco, Silvia ^a   Ficarra, Vincenzo ^a   Artibani, Walter ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

GnRH agonist; LhRH agonist; Prostatic neoplasms; Testosterone

Indexed keywords

ABARELIX; ATRIGEL; BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; CANCER SURGERY; CASTRATION; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FORMULATION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; RADIOIMMUNOASSAY; REVIEW; SEARCH ENGINE; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; DRUG MONITORING; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 65949104830     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209352     Document Type: Review

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Heidenreich A, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Schmid HP, Zattoni F: EAU guidelines on prostate cancer. Downloaded at http://www.uroweb. org/filead-min/user-upload/Guidelines/07-Prostate- Cancer-2007.pdf.
3. NCCN Clinical practice guidelines in oncology. Prostate cancer v. 1.2008. Downloaded at http://www.nccn.org/professionals/physi-cian-gls/PDF/prostate. pdf.
4. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ: Singletherapy androgen suppression in men with advanced prostate cancer: a systematic review and metaanalysis. Ann Intern Med 2000;132:566-577.
5. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-1624.
6. Berges R, Bello U: Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006;22:649-655.
7. Sartor O: Eligard: a new form of treatment for prostate cancer. Eur Urol Suppl 2006;5:905-910.
8. Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC: A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-1914.
9. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC: A clinical study of 22.5 mg La-2550:a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199-1203.
10. Berges R: Eligard: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 2005;4:20-25.
11. Phillips B, Ball C, Sackett D, et al: Levels of evidence and grades of recommendation. Oxford Centre for Evidence-Based Medicine. Downloaded at http://www.cebm.net/ levels-of-evidence.asp#levels.
12. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-1024.
13. Isurugi K, Kondo Y, Hirasawa K, et al: Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists. Nippon Hinyokika Gakkai Zasshi 1989;80:1466-1470.
14. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL: Orchiectomy versus long-acting D -Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987;59:248-254.
15. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-508.
16. Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA Jr, Scott M, Kennealey G, Gau TC: Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology 1991;37:46-51.
17. Rohl HF, Beuke HP: Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992;26:11-14.
18. Lin BJ, Chen KK, Chen MT, Chang LS: The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 1994;43:834-837.
19. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PE, Smith JA, Caplan RJ, Kennealey GT; for the Zoladex prostate study group: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urolog y 1995;46:220-226.
20. Fernandez del Moral P, Dijkman GH, Debruyne FMJ, Witjes WPJ, Kolvenbag GJCM, for the Dutch South East Cooperative Urological Group: Three-month depot of Goserelin acetate: clinical efficacy and endocrine profile. Urology 1996;48:894-900.
21. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC, for the South African Triptorelin Study Group: Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003;92:226-231.
22. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J: Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res 2004;62:252-258.
23. Oefelein MG: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685- 1688.
24. Oefelein MG: Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 1999;54:694-699.
25. Oefelein MG, Cornum R: Failure to achieve castrate levels of testosterone during luteinizing hormone-releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164:726-729.
26. Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R, for the VIADUR Study Group: Evaluat ion of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urolog y 2000;55:639-642.
27. Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, Maymone SS, Cosciani Cunico S, Zanollo A, Montagna G, Frongia M, Jacobellis U: Three-month formulation of goserelin acetate (Zoladex 10.8-mg depot) in advanced prostate cancer: results from an Italian open multicenter trial. Urol Int 2003;70:316-320.
28. Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC: An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003;62:319-323.
29. Pettersson B, Varenhorst E, Petas A, Sandow J: Duration of testosterone suppression after a 9.45-mg implant of the GnRH-analogue Buserelin in patients with localised carcinoma of the prostate. A 12-month follow-up study. Eur Urol 2006;50:483-489.
30. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS: A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533-536.
31. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventos CX, Catalan R, Reventos J: Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006;77:135-138.
32. Yri OE, Bjoro T, Fossa SD: Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
33. Tombal B, Berges R: Eligard: advantages for optimal testosterone control. Eur Urol Suppl 2006;5:900-904.
34. National Comprehensive Cancer Network: Prostate cancer. Treatment guidelines for patients. Version II. Last update: 2001.
35. Tombal B, Berges R: How good do current LhRH agonists control testosterone? Can this be improved with Eligard? Eur Urol Suppl 2005;4:30-36.
36. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T: Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;2:CD001526.
37. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-1498.
38. Klotz L: Combined androgen blockade: an update. Urol Clin North Am 2006;33:161-166.